During the past decade, Universitätsklinikum Erlangen - Hautklinik conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 14 clinical trials were completed, i.e. on average, 116.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 7 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Erlangen - Hautklinik" #1 sponsor was "Pfizer" with 6 trials, followed by "University Hospital Erlangen" with 3 trials sponsored, "Amgen" with 2 trials sponsored, "Concert Pharmaceuticals" with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Erlangen - Hautklinik" #1 collaborator was "FGK Clinical Research GmbH" with 1 trials as a collaborator, "Granzer Regulatory Consulting & Services" with 1 trials as a collaborator, "Shire" with 1 trials as a collaborator and "Ticeba GmbH" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Erlangen - Hautklinik" are "Psoriasis" (7 trials), "Melanoma (Skin)" (4 trials), "Alopecia Areata" (2 trials), "Plaque Psoriasis" (2 trials) and "Psoriatic Arthritis" (2 trials). Many other conditions were trialed in "Universitätsklinikum Erlangen - Hautklinik" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Erlangen - Hautklinik" are "Drug" (20 trials), "Biological" (7 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Etanercept" (3 trials), "Apremilast" (2 trials), "Vemurafenib" (2 trials) and "therapeutic autologous dendritic cells" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Erlangen - Hautklinik" are 26 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Erlangen - Hautklinik". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Universitätsklinikum Erlangen - Hautklinik, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Erlangen - Hautklinik, 5 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 0 trials that are defined as “Not Applicable".